{
    "nctId": "NCT01401166",
    "briefTitle": "Participant Preference of Subcutaneous (SC) Versus Intravenous (IV) Herceptin (Trastuzumab) in Human Epidermal Growth Factor Receptor (HER) 2-Positive Early Breast Cancer",
    "officialTitle": "A Randomized, Multi-Center Cross-Over Study to Evaluate Patient Preference and Health Care Professional (HCP) Satisfaction With Subcutaneous (SC) Administration of Trastuzumab in HER2-Positive Early Breast Cancer (EBC)",
    "overallStatus": "COMPLETED",
    "conditions": "Breast Neoplasms",
    "studyType": "INTERVENTIONAL",
    "phase": "PHASE2",
    "allocation": "RANDOMIZED",
    "primaryPurpose": "HEALTH_SERVICES_RESEARCH",
    "enrollmentCount": 488,
    "primaryOutcomeMeasure": "Percentage of Participants by Preferred Method of Drug Administration",
    "eligibilityCriteria": "Inclusion Criteria:\n\n* Histologically confirmed HER2-positive primary breast cancer\n* No evidence of residual, locally recurrent, or metastatic disease after completion of surgery and chemotherapy (neo-adjuvant or adjuvant)\n* Completed neo-adjuvant chemotherapy prior to entry, if received\n* At least 8 remaining cycles out of the total 18 planned 3-week cycles, if received IV Herceptin\n* Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1\n\nExclusion Criteria:\n\n* History of other malignancy, except for ductal carcinoma in situ of the breast, curatively treated carcinoma in situ of the cervix, basal cell carcinoma, or other curatively treated malignancies of which the participant has been disease-free for at least 5 years\n* Inadequate bone marrow function\n* Impaired liver function\n* Inadequate renal function\n* Serious cardiovascular disease\n* Human immunodeficiency virus or hepatitis B or C infection\n* Prior maximum cumulative dose of doxorubicin greater than (\\>) 360 milligrams per meter-squared (mg/m\\^2) or epirubicin \\>720 mg/m\\^2 or equivalent",
    "sex": "FEMALE",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}